BAY 11-7082 Is a Broad-Spectrum Inhibitor with Anti-Inflammatory Activity against Multiple Targets
Figure 2
Effect of BAY on transcriptional activation of NF-κB. (a left panel, b, and g) Translocated or phosphorylated levels of NF-κB subunits from nucleus (a) or whole lysates (b) of RAW264.7 cells (a, b, and g left panel) or peritoneal macrophages (g right panel) treated with BAY (15 μM) in the presence or absence of LPS (1 μg/mL) for indicated times, evaluated by immunoblotting. (c left panel to f) HEK293 cells cotransfected with NF-κB-Luc construct (1 μg/mL) and β-gal (transfection control) were treated with BAY (0 to 20 μM) in the presence or absence of PMA (100 nM) or by cotransfection with NF-κB activation inducers (MyD88, TRIF, and TBK1). Luciferase activity was measured using a luminometer. (a right panel and c right panel) Viability of RAW264.7 (a right panel) and HEK293 (c right panel) cells treated with BAY (0 to 20 or 30 μM) for 2 or 24 h was examined by MTT assays. * and ** compared to the control.
